Bringing a medicinal product to market requires far more than demonstrating quality, safety, and efficacy. Companies must also demonstrate that the product is unlikely to pose an unacceptable risk to the environment. An incomplete or poorly prepared Environmental Risk Assessment (ERA) can lead to regulatory questions, additional data requests, prolonged review timelines, and unnecessary costs. With the EMA’s revised guideline now in force, applicants are expected to provide increasingly robust scientific and regulatory justification as part of all marketing authorisation applications. As regulatory expectations continue to evolve, many pharmaceutical companies rely on environmental risk assessment services to ensure their submissions meet current scientific and regulatory standards.

As a result, many pharmaceutical companies search for Top ERA service providers ranked for pharma submissions when planning regulatory submissions. In reality, however, choosing the right partner is far more important than choosing a provider based on a generic ranking. Successful submissions depend on scientific expertise, regulatory knowledge, and the ability to prepare submission-ready documentation that meets the expectations of health authorities from the outset.

This is where professional environmental risk assessment services create real value. Rather than treating ERA as a standalone regulatory obligation, experienced consultants integrate environmental assessments into the overall submission strategy, helping companies minimise regulatory risk, avoid unnecessary delays, and accelerate market access. Working with an experienced medical writing consultant further strengthens the quality and consistency of submission-ready documentation by ensuring that scientific data is presented clearly and in line with regulatory expectations. At Billev Pharma East, Environmental Risk Assessment forms part of our comprehensive Regulatory Affairs services, alongside toxicological risk assessment, lifecycle management, eCTD publishing, and end-to-end regulatory support for pharmaceutical companies worldwide.

How pharmaceutical companies should prepare for an Environmental Risk Assessment

Preparing an Environmental Risk Assessment (ERA) should not be treated as a standalone regulatory task completed shortly before submission. Instead, pharmaceutical companies should integrate ERA planning into their regulatory strategy from the early stages of product development. Early preparation allows sufficient time to collect the necessary scientific data, identify potential environmental concerns, and address any data gaps before they become critical during the marketing authorisation review. EMA requires an ERA for all new marketing authorisation applications for human medicinal products, following a stepwise approach that begins with Phase I exposure assessment and, where applicable, progresses to Phase II environmental fate and ecotoxicity studies.

Companies should also ensure that the assessment is prepared by professionals with expertise in regulatory affairs, environmental science, ecotoxicology, and pharmaceutical submissions. A high-quality ERA requires more than performing calculations. It involves evaluating the active substance, calculating predicted environmental concentrations (PEC), determining whether further Phase II testing is required, interpreting study results, preparing robust scientific justifications where applicable, and compiling submission-ready documentation that aligns with current regulatory expectations. Every assessment should be scientifically sound, fully documented, and tailored to the specific medicinal product and submission pathway.

Finally, pharmaceutical companies should choose a partner capable of supporting the entire product lifecycle rather than only producing a single report. Environmental requirements may change following new indications, extensions, or other post-authorisation activities, making ongoing regulatory expertise just as important as the initial assessment. Working with an experienced provider of environmental risk assessment services helps companies minimise regulatory risk, streamline submissions, and ensure their ERA remains compliant throughout the lifecycle of the medicinal product.

Why choose Billev Pharma East for environmental risk assessment services?

Preparing an Environmental Risk Assessment is about far more than completing a regulatory requirement—it is about submitting scientifically robust documentation that supports a successful marketing authorisation. At Billev Pharma East, we combine regulatory expertise, scientific knowledge, strategic project management, and medical writing services to deliver environmental risk assessment services that help pharmaceutical companies achieve compliant, efficient, and submission-ready dossiers. Rather than treating ERA as an isolated document, we integrate it into your overall regulatory strategy to minimise risk, reduce delays, and support faster market access.

Our specialists support every stage of the process, from determining the appropriate regulatory strategy and preparing Phase I and Phase II assessments to compiling submission-ready documentation for the relevant CTD module that aligns with current EMA expectations. We also provide end-to-end Regulatory Affairs support, including dossier preparation, eCTD publishing, lifecycle management, product information, CMC documentation, and communication with competent authorities. This integrated approach ensures that your ERA is fully aligned with the rest of your marketing authorisation application, reducing the likelihood of inconsistencies or avoidable regulatory questions. Our Regulatory Affairs services specifically include Environmental Risk Assessment (ERA) as part of our comprehensive submission support.

Unlike providers that focus solely on preparing an ERA report, Billev Pharma East delivers fully integrated Regulatory Affairs support. Our experts ensure that the Environmental Risk Assessment is scientifically robust, fully aligned with the Common Technical Document (CTD), and consistent with the overall regulatory strategy, helping pharmaceutical companies reduce regulatory risk and avoid unnecessary delays throughout the submission process.

When pharmaceutical companies search for Top ERA service providers ranked for pharma submissions, they are ultimately looking for a partner they can trust with one of the most critical parts of their regulatory submission. At Billev Pharma East, we work as an extension of your regulatory team, combining technical expertise with practical experience across European and global regulatory procedures. Whether you require support for a single ERA or a complete regulatory submission, we deliver tailored solutions that help you navigate regulatory complexity with confidence and bring your products to market successfully.

What makes a top partner for environmental risk assessment services?

Many pharmaceutical companies search for the Top ERA service providers ranked for pharma submissions, assuming that selecting the right provider is simply a matter of finding the highest-ranked company. In reality, there is no official regulatory ranking of ERA providers. What truly differentiates a reliable partner is their ability to prepare scientifically robust, submission-ready documentation that aligns with current regulatory expectations and supports a successful marketing authorisation.

An experienced provider of environmental risk assessment services should offer much more than the preparation of an ERA report. They should understand the complete regulatory pathway, determine whether a Phase I assessment is sufficient or whether Phase II studies are required, evaluate available scientific and ecotoxicological data, prepare robust justifications where appropriate, and ensure the assessment is fully integrated into the marketing authorisation dossier. Equally important is the ability to anticipate regulatory questions before submission, reducing the likelihood of deficiencies, requests for additional information, or avoidable delays during the review process.

The most valuable partners also provide long-term regulatory support beyond the initial submission. Environmental requirements may evolve throughout a product’s lifecycle due to variations, line extensions, or new scientific evidence. Working with a provider that combines ERA expertise with broader Regulatory Affairs capabilities ensures consistency across the dossier and enables companies to respond efficiently to changing regulatory expectations. Ultimately, the best choice is not the provider with the strongest marketing claims, but the one with the scientific expertise, regulatory experience, and end-to-end submission capabilities needed to support successful pharmaceutical submissions. Rather than relying on generic online rankings, pharmaceutical companies should evaluate potential partners based on their scientific expertise, regulatory experience, lifecycle support, and ability to deliver fully integrated environmental risk assessment services as part of the overall submission strategy.

Choose a partner that strengthens your regulatory submission

A well-prepared Environmental Risk Assessment is more than a regulatory requirement—it is an important contributor to a smooth and successful marketing authorisation process. By investing in high-quality environmental risk assessment services, pharmaceutical companies can reduce regulatory uncertainty, minimise delays, and ensure their submissions meet the latest EMA expectations from the outset. ERA is required for all new marketing authorisation applications and may also be necessary for certain lifecycle changes where environmental exposure increases.

At Billev Pharma East, we help pharmaceutical companies transform complex regulatory requirements into clear, submission-ready solutions. From ERA strategy and scientific assessments to complete Regulatory Affairs support, eCTD publishing, and lifecycle management, our experts provide end-to-end services tailored to your product and regulatory pathway.

Whether you require support with a single Environmental Risk Assessment or complete Regulatory Affairs outsourcing, Billev Pharma East provides tailored environmental risk assessment services that help pharmaceutical companies prepare scientifically robust, compliant, and submission-ready dossiers. Contact our experts today to discuss your upcoming project and discover how we can support every stage of your regulatory submission.

Frequently asked questions

Sources: 1 – European Medicines Agency (EMA). (2024). Guideline on the environmental risk assessment of medicinal products for human use – Revision 1 (EMEA/CHMP/SWP/4447/00 Rev. 1 – Corr.), 2 – European Medicines Agency (EMA). (2024). Environmental risk assessment of medicinal products for human use – Scientific guideline, 3 – European Medicines Agency (EMA). (n.d.). Pre-authorisation guidance for human medicinal products, 4 – European Parliament and the Council of the European Union. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use.

Image credits:

In-article images: Pexels

In-article images: Pexels

Hero image: Pexels